As the demand for meaningful innovation in healthcare grows, impact investors and venture philanthropists are stepping in to support early-stage life science and healthcare companies. These funders are driven not only by the potential for financial return, but also by the goal of advancing health equity, improving patient outcomes, and addressing critical unmet needs.

This 50-minute panel brings together leaders in impact investing and venture philanthropy to discuss how they deploy capital to catalyze innovation, particularly in areas often overlooked by traditional venture investors. Panelists will explore how they define and measure impact, what they look for in early-stage ventures, and how they work with founders to align mission with milestone-based growth. Hear from investors who are helping shape a more inclusive and outcomes-focused healthcare future.

In 2022, WHO announced in their factsheet that 1 in every 8 people in the world live with a mental disorder. With ongoing efforts to raise awareness and reduce stigma, there continues to be a high demand for new solutions and investors are taking notice. From digital therapeutics and neurotechnology to novel therapeutics and care delivery models, early-stage companies are pushing the boundaries of how mental and behavioral health can be diagnosed, treated, and managed.

This 50-minute panel will feature investors actively backing innovation in mental and behavioral health. Panelists will discuss where they see the most promising opportunities, how they evaluate clinical and commercial potential in a complex and often fragmented market, and what it takes for early-stage companies to stand out. The conversation will also explore how stigma, reimbursement challenges, and regulatory pathways impact investment decisions—and how emerging technologies and models of care are reshaping the landscape.

For companies developing tools for anxiety, depression, addiction, neurodevelopmental disorders, or serious mental illness, or for investors who are looking more into investing in mental and behavioral health-related disorders, this session will offer practical insights into how investors are supporting the next generation of mental health solutions.

Oncology remains one of the most dynamic and competitive areas in life science innovation, attracting sustained investor interest and driving scientific breakthroughs across diagnostics, therapeutics, and digital platforms. However, many challenges are afoot – with increasing scientific complexity, regulatory demands, and rising development costs, early-stage oncology companies must demonstrate not only novel science, but real potential for clinical and commercial impact.

This 50-minute panel will bring together active investors and strategic partners focused on oncology innovation. Panelists will explore which technologies and modalities are capturing attention as well as future outlook on how this field will continue to evolve. The discussion will also cover what makes an oncology startup stand out in a crowded field, how investors assess differentiation and de-risking at early stages, and where the biggest unmet needs remain.

For any company that is addressing oncology – from novel therapeutics to preventative diagnostics – this session will offer valuable insights into partnering and funding strategies at the cutting edge of cancer care.

Many large corporations establish corporate venture or innovation arms to invest and partner with life science and healthcare companies. However, every corporate venture capital firm has a unique approach and strategy in investment, and their ties to the corporation can differ. Some invest only in areas that complement the parent company’s existing interest areas, while some may source for opportunities beyond those interest areas.

This 50-minute panel will feature leaders from the corporate venture arms of global pharma, biotech, and medtech companies, and other major corporations in the healthcare industry. Panelists will discuss how they identify and evaluate early-stage opportunities, how their investment criteria differ from institutional VCs, and how they balance strategic alignment with return potential. The conversation will also cover how startups can navigate relationships with CVCs, what they can expect beyond capital, how collaboration may evolve post-investment, and how to position themselves for success with strategic partners.

For anyone who is seeking investment from a CVC, this panel will uncover insights from active corporate VC firms and how they seek to drive innovation, accelerate R&D, and bring transformative solutions to market.

Diagnostics are playing an increasingly central role in the future of healthcare by enabling earlier detection, more precise treatment, and better patient outcomes. From next-generation sequencing and liquid biopsy to digital and AI-powered tools, diagnostics are transforming how we understand and manage disease, ultimately leading to better patient outcomes.

This 50-minute panel will feature investors and strategic partners focused on early-stage diagnostics innovation. Panelists will explore what makes a diagnostic technology attractive from both a clinical and commercial standpoint, how they evaluate reimbursement potential and regulatory pathways, and where they see the biggest unmet needs. The discussion will also highlight how diagnostics companies can differentiate themselves, gain early traction, and successfully partner with investors or industry leaders.

For fundraising entrepreneurs developing novel solutions in oncology, infectious disease, chronic conditions, or personalized medicine, this session will offer practical insights on funding, positioning, and scaling impactful diagnostic solutions and how your company can stand out to active investors and strategic partners.

For many early-stage life science companies, partnering with Big Pharma is a critical milestone, as these major pharmaceutical companies offer access to global expertise, resources, and commercialization pathways. But competition is fierce, and successful partnerships require more than great science. They demand clear differentiation, strong data, strategic alignment, and a compelling case for unmet need.

This 50-minute panel will feature business development and venture leaders from major pharmaceutical companies who are actively scouting for innovation across therapeutics, diagnostics, digital health, and enabling technologies. Panelists will share what they look for in early-stage companies, how their teams evaluate external opportunities, and when in the development cycle they are willing to engage. The discussion will also explore trends shaping pharma’s innovation strategy and how startups can position themselves for long-term, high-impact partnerships.

Whether you are aiming for a co-development deal, licensing agreement, or strategic investment, this session offers an inside look at how big pharm thinks, and what it takes to stand out.

This panel focuses on understanding how family offices view direct investments in early-stage healthcare opportunities (seed – series A) and how they differ from and compare to VCs. Topics may include:

• Primary differences between institutional VCs and family office investors
• How family offices source investments / how to get on their radar
• Trends in the early-stage healthcare investment space

The primary goal of this panel is to help entrepreneurs understand how family offices view early-stage investments in the healthcare space and best practices for approaching, pitching, and working with these groups as well as debunking some common misconceptions about family offices.